Skip to main content

Peer Review reports

From: The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

Original Submission
20 Jan 2024 Submitted Original manuscript
23 Apr 2024 Reviewed Reviewer Report
29 Apr 2024 Reviewed Reviewer Report
8 May 2024 Author responded Author comments - Hao Zeng
Resubmission - Version 2
8 May 2024 Submitted Manuscript version 2
14 May 2024 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
15 May 2024 Editorially accepted
8 Jun 2024 Article published 10.1186/s12885-024-12388-2

You can find further information about peer review here.

Back to article page